What prices were reported for Harpreet S. Dhaliwal’s Vaxcyte (PCVX) share dispositions?

The tax-withholding dispositions were reported at $61.98 per share. These transactions covered 292 shares on February 28, 2026 and 465 shares on March 2, 2026, all classified as payment of tax liability by delivering securities.

Vaxcyte (NASDAQ: PCVX) CTO reports stock awards and tax-related share disposals

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Vaxcyte, Inc. reported insider equity activity by Chief Technical Ops Officer Harpreet S. Dhaliwal. On February 26, 2026, Dhaliwal received grants of 53,409 shares of common stock and 46,424 stock options, both at a reported price of $0.00 per share as awards. The common stock grant represents restricted stock units that vest over time starting September 7, 2026. On February 28 and March 2, 2026, a total of 757 shares of common stock were disposed of at $61.98 per share to cover tax withholding obligations upon RSU vesting. After these transactions, Dhaliwal directly held 76,580 shares of common stock.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Dhaliwal Harpreet S.

Role Chief Technical Ops Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	465	$61.98	$29K
Tax Withholding	Common Stock	292	$61.98	$18K
Grant/Award	Stock Option (right to buy)	46,424	$0.00	--
Grant/Award	Common Stock	53,409	$0.00	--

Holdings After Transaction: Common Stock — 76,580 shares (Direct); Stock Option (right to buy) — 46,424 shares (Direct)

Footnotes (1)

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/02/2026 - 08:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dhaliwal Harpreet S.

(Last)

(First)

(Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS

94070

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Technical Ops Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A		53,409⁽¹⁾	A	$0	77,337	D
Common Stock	02/28/2026		F		292⁽²⁾	D	$61.98	77,045	D
Common Stock	03/02/2026		F		465⁽²⁾	D	$61.98	76,580	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$60	02/26/2026		A		46,424		⁽³⁾	02/26/2036	Common Stock	46,424	$0	46,424	D

Explanation of Responses:

1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

2. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

3. 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Remarks:

	Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Vaxcyte (PCVX) report for Harpreet S. Dhaliwal?

Vaxcyte reported that Chief Technical Ops Officer Harpreet S. Dhaliwal received stock and option awards, and disposed of shares for tax withholding. The activity reflects routine equity compensation and related tax-withholding dispositions tied to restricted stock unit vesting.

How many Vaxcyte (PCVX) shares did Harpreet S. Dhaliwal acquire in awards?

On February 26, 2026, Harpreet S. Dhaliwal acquired awards covering 53,409 shares of common stock and 46,424 stock options. These grants were reported at a price of $0.00 per share as they represent equity compensation rather than open-market purchases.

Why did Harpreet S. Dhaliwal dispose of Vaxcyte (PCVX) shares in this Form 4?

Dhaliwal disposed of Vaxcyte shares to cover tax withholding obligations when restricted stock units vested. The Form 4 notes the transactions as tax-withholding dispositions, meaning shares were surrendered back to the issuer rather than sold in the open market.

How many Vaxcyte (PCVX) shares did Harpreet S. Dhaliwal hold after the reported transactions?

Following the reported equity award grants and tax-withholding share dispositions, Harpreet S. Dhaliwal directly held 76,580 shares of Vaxcyte common stock. This figure reflects his direct ownership after all transactions disclosed in the Form 4.

How do the Vaxcyte (PCVX) RSU awards to Harpreet S. Dhaliwal vest over time?

The restricted stock units vest over multiple dates. One-quarter of the shares vest on September 7, 2026, and one-eighth of the shares vest every six months thereafter, conditioned on Dhaliwal’s continuous service with Vaxcyte through each vesting date.